首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1733724

2026 年至 2032 年乾粉吸入器 (DPI) 市場按產品類型、應用、銷售管道和地區分類

Dry Powder Inhaler (DPI) Market by Product Type (Capsule-based, Blister-based, Reservoir/Cartridge-based), Application (Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Asthma), Sales Channel (Offline, Online), & Region for 2026-2032

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄

乾粉吸入器（DPI）市場評估 - 2026-2032

市場快速擴張的促進因素包括慢性呼吸系統疾病盛行率的不斷上升、DPI 的技術發展以及自我治療趨勢的日益成長。據 Verified Market Research 分析師稱，乾粉吸入器市場預計在 2024 年價值約為 184 億美元，預計在預測期內將達到 244.7 億美元的估值。

呼吸系統疾病發病率的上升、DPI設備技術的改進以及患者對快速有效吸入療法的需求推動了乾粉吸入器（DPI）市場的強勁擴張。基於此，預計2026年至2032年市場將以3.6%的複合年成長率成長。

乾粉吸入器（DPI）市場：定義/概述

乾粉吸入器 (DPI) 是醫療設備。與使用推進劑排出藥物的傳統吸入器不同，DPI 利用患者的呼吸來吸入粉末。它們被廣泛用於治療氣喘、慢性阻塞性肺病(COPD) 和其他肺部疾病等呼吸系統疾病，因為它們提供了一種將支氣管擴張劑、皮質類固醇和其他藥物直接輸送到呼吸道的便捷有效的方法。

影響 DPI 市場成長軌跡的關鍵促進因素有哪些？

慢性阻塞性肺病(COPD)、氣喘和囊腫纖維化等呼吸系統疾病的盛行率不斷上升是 DPI 市場的主要驅動力。同樣，《2018 年全球氣喘報告》估計，氣喘影響全球超過 3.39 億人。需要吸入治療的患者數量不斷成長，推動了對有效且便利的 DPI 設備的需求。

與標準定量吸入器 (MDI) 和霧化器相比，DPI 具有許多優勢，包括便攜性、使用方便性和無需推進劑。這些優勢使得DPI對患者更具吸引力，從而導致更高的接受度。《氣霧劑醫學與肺部藥物輸送雜誌》（2019 年）發表的一項調查發現，89% 的患者更喜歡 DPI 而不是定量吸入器，因為它們易於使用且便於攜帶。

根據聯合國統計，世界人口正在老化，預計到 2050 年，60 歲及以上人口的數量將增加一倍。老年人更容易受到呼吸道感染疾病，因此對更易於使用且對該患者群體更有效的 DPI 設備的需求日益成長。

此外，DPI 設備設計、藥物配方和製造流程的不斷進步正在提高這些產品的效率和使用率。例如，多劑量和呼吸驅動的DPI的開發提高了患者的依從性和便利性。例如，發表在《BMJ Open》上的一項研究發現，在英國將 10% 的計量吸入器 (MDI) 替換為乾粉吸入器 (DPI) 每年可減少 58,000 噸碳排放。

乾粉吸入器（DPI）市場中的公司面臨哪些挑戰？

正確的吸入技術對於使用 DPI 有效輸送藥物至關重要，但這對於小孩、老人和協調性差的患者來說可能比較困難。不一致的呼吸技巧會導致輸送到肺部的藥物減少，進而影響治療的效果。

創建穩定有效的 DPI 配方非常困難。粉末必須足夠細才能有效吸入，同時具有適當的流動特性才能達到最佳分散。此外，有些藥物具有吸濕性，可能會積聚周圍的水分，從而影響其在 DPI 內的穩定性和功能。

此外，DPI 還與其他吸入技術（如壓力定量吸入器 (MDI) 和霧化器）競爭。 MDI 因其易於使用而受到青睞，而霧化器適合那些難以掌握吸入技術或需要更高劑量藥物的人，從而限制了 DPI 在某些領域的市場成長。

The increasing prevalence of chronic respiratory diseases, technological developments in DPIs, and the growing inclination towards self-medication are all contributing to the market's rapid expansion. According to the analyst from Verified Market Research, the dry powder inhaler market is estimated to reach a valuation of USD 24.47 Billion over the forecast subjugating around USD 18.4 Billion valued in 2024.

The growing rates of respiratory illnesses, improved DPI device technology, and patient demand for quick and efficient inhalation treatment are all contributing to the market's strong expansion for dry powder inhalers, or DPIs. It enables the market to grow at a CAGR of 3.6% from 2026 to 2032.

Dry Powder Inhaler (DPI) Market: Definition/ Overview

A Dry Powder Inhaler (DPI) is a medical device that administers medication to the lungs in the form of dry powder. Unlike regular inhalers, which utilize a propellant to dispense medication, DPIs use the patient's breath to inhale the powder. These devices are widely used to treat respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other lung diseases, as they provide a convenient and effective way to deliver bronchodilators, corticosteroids, and other medications directly to the respiratory tract.

What are the Key Drivers Shaping the Growth Trajectory of the DPI Market?

The rising prevalence of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis is a significant driver of the DPI market. Similarly, the Global Asthma Report 2018 predicts that asthma affects more than 339 million individuals worldwide. The expanding number of patients requiring inhalation therapy is driving the demand for effective and convenient DPI devices.

DPIs have various advantages over standard metered-dose inhalers (MDIs) and nebulizers, including portability, convenience of use, and the elimination of propellants. These advantages make DPIs more enticing to patients, resulting in higher adoption. According to research published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery (2019), 89% of patients preferred DPIs to metered-dose inhalers because of their ease of use and mobility.

The global population is aging, with the number of individuals aged 60 and older anticipated to double by 2050, according to the United Nations. Older persons are more vulnerable to respiratory infections, increasing the demand for DPI devices that are simpler to use and more effective for this patient population.

Furthermore, continuous advancements in DPI device design, medication formulations, and manufacturing processes improve the efficiency and use of these products. For example, the development of multi-dose DPIs and breath-actuated DPIs has increased patient compliance and convenience. For instance, according to a study published in BMJ Open, switching 10% of metered-dose inhalers (MDIs) to dry powder inhalers (DPIs) in the UK could reduce carbon emissions by 58,000 tons annually.

What are the Challenges Faced by Companies in the Dry Powder Inhaler (DPI) Market?

Proper inhaling methods are essential for effective medication delivery with a DPI, which can be challenging for small children, elderly patients, and individuals with coordination issues. Inconsistent breathing procedures cause less medication accumulation in the lungs, potentially jeopardizing therapy efficacy.

Creating stable and effective DPI compounds is difficult. The powder should be fine enough for efficient inhalation while also having appropriate flow characteristics for optimum dispersion. Furthermore, some drugs are hygroscopic, accumulating moisture from their surroundings, affecting their stability and function within a DPI.

Furthermore, DPIs compete with other inhalation technologies, such as pressurized metered dosage inhalers (MDIs) and nebulizers. MDIs are recommended for their ease of use, whereas nebulizers are appropriate for people suffering from inhalation techniques or requiring high medicine doses, which limits market growth for DPIs in certain segments.

Category-Wise Acumens

How Does the Dominance of Capsule-based DPIs Contribute to the Overall Market?

According to VMR Analysis, the capsule-based segment is estimated to hold the largest market share during the forecast period. Capsule-based DPIs are designed to be simple and user-friendly for patients. They frequently have a simple loading mechanism that requires little effort to prepare the dose. Furthermore, capsule-based devices are small and lightweight, which improves portability and convenience for patients on the move.

Capsule-based DPIs provide better dosage precision than other device types. The pre-metered capsules ensure that each dose includes the exact amount of medication, reducing the risk of under- or overdosing. This precision contributes to improved therapeutic efficacy and patient outcomes.

Furthermore, DPI capsules work well with a wide range of respiratory drugs, including bronchodilators, corticosteroids, and combination therapy. This adaptability enables healthcare providers to modify treatment strategies to particular patient demands, resulting in the widespread use of capsule-based devices.

What Drivers Support the Maximum Usage of DPI in Treating COPD?

The chronic obstructive pulmonary disease (COPD) segment is estimated to dominate the dry powder inhaler market during the forecast period. COPD is a prominent cause of illness and mortality worldwide, with a large and increasing prevalence. The World Health Organization estimates that over 65 million people suffer from COPD globally. This vast patient population creates a demand for effective inhalation medicines for COPD therapy, such as DPIs.

COPD is primarily controlled with inhalation medicines, which effectively deliver pharmaceuticals to the lungs. DPIs have been a popular alternative among COPD patients due to their portability, convenience, and ability to administer exact medicine doses precisely to the afflicted parts of the respiratory system.

Additionally, there is an increasing emphasis on preventative healthcare strategies for respiratory disorders such as COPD. DPIs serve an important role in providing targeted drug delivery, reducing exacerbations, and improving overall health outcomes for COPD patients, which has fueled their acceptance in this segment.

Country/Region-wise Acumens

What Unique Market Dynamics Contribute to North America's Leadership in the Market?

According to VMR Analyst, North America is estimated to dominate the dry powder inhaler market during the forecast period. Asthma and chronic obstructive pulmonary disease (COPD) are common respiratory disorders in North America, particularly in the United States. According to the Centers for Disease Control and Prevention, more than 25 million Americans have asthma, while an estimated 16 million people in the United States suffer from COPD. This vast patient population increases the demand for effective inhalation medicines such as DPIs.

North America, led by the United States, has a well-developed healthcare system that provides extensive access to innovative medical technologies and treatments. This allows for the adoption of innovative DPI equipment and promotes the growth of the DPI market in the region. The presence of important market participants, as well as ongoing R&D initiatives, contribute to the region's dominant position.

Furthermore, the availability of favorable payment rules for respiratory drugs and equipment increases patient access to DPIs. This, combined with the population's strong spending power, makes North America an appealing market for DPI producers, driving overall regional market growth.

What Factors Lead to Asia Pacific Experiencing the Fastest Growth in the Market?

The Asia Pacific region is estimated to exhibit the highest growth within the dry powder inhaler market during the forecast period. The Asia-Pacific region includes a sizable and expanding patient population suffering from respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. According to the Global Asthma Report 2018, the Asia-Pacific region has the most people with asthma, accounting for more than 175 million cases. This high illness burden drives the region's adoption of effective inhalation medicines such as DPIs.

Governments in the Asia-Pacific region are boosting their investments in healthcare access and infrastructure, particularly in emerging countries. This, together with increased awareness of respiratory disorders and the benefits of sophisticated inhalation devices among healthcare professionals and patients, is driving the DPI market in this region.

Furthermore, leading multinational pharmaceutical and medical device businesses are increasing their presence and manufacturing capabilities in Asia-Pacific to meet rising demand. Also, strategic collaborations between major corporations and local players are permitting the launch of innovative DPI products adapted to the needs of the regional market, which is driving the Asia-Pacific DPI market forward.

Competitive Landscape

The dry powder inhaler (DPI) market is characterized by fierce competition among leading competitors, which is driven by ongoing innovation and developments in device technology. Additionally, the rising prevalence of respiratory disorders has prompted significant investment in R&D, resulting in the launch of new formulations and combination medicines.

Some of the prominent players operating in the dry powder inhaler (DPI) market include:

GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novartis AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., 3M Pharmaceuticals, Hovione, MannKind Corpo.

Latest Developments

In February 2021, Catalent Inc. purchased Acorda Therapeutics Inc., expanding its DPI production capabilities and adding a commercial-stage pharmaceutical to its portfolio. This acquisition highlights the growing importance of DPI treatments in respiratory and neurological illnesses.

In April 2019, Hovione Technology acquired the rights to develop and commercialize Dr. Klaus-Dieter Beller's Papillon DPI, a revolutionary and cost-effective dry powder inhaler technology.